Observations placeholder

Verteporfin (trade name Visudyne), a benzoporphyrin derivative, is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 689 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.  Verteporfin is given intravenously, 15 minutes before laser treatment.

Verteporfin is also used off-label for the treatment of central serous retinopathy

Side effects

Most common side effects are blurred vision, headache, and local effects at the injection site. Also, photosensitivity; it is advised to avoid exposure to sunlight and unscreened lighting until 48 hours after the injection of verteporfin

On Feb, 18, 2016: 2,306 people reported to have side effects when taking Visudyne. Among them, 4 people (0.17%) have Hallucination.

Time on Visudyne when people have Hallucination  :

On Feb, 6, 2016: 2,306 people reported to have side effects when taking Visudyne. Among them, 16 people (0.69%) have Death.

Time on Visudyne when people have Death  :

Gender of people who have Death when taking Visudyne  :

Age of people who have Death when taking Visudyne  :

Top conditions involved for these people  :

1. Macular degeneration (10 people, 62.50%)
2. Age-related macular degeneration (2 people, 12.50%)